Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Trial Profile

A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms JAVELIN Merkel 200
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 22 Oct 2019 According to an EMD Serono media release, three-year results from Part A (n=88) of this study will be presented at the First International Symposium on Merkel Cell Carcinoma.
    • 22 Oct 2019 Results presented in an EMD Serono media release.
    • 26 Sep 2019 According to an EMD Serono media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top